Diclofenac Sodium
| 證據等級: L5 | 預測適應症: 0 個 |
目錄
- Diclofenac Sodium
- Diclofenac Sodium: Repurposing Evaluation on Hold — No TxGNN Predictions Available
The txgnn-pipeline skill covers training and deployment — not relevant here. Proceeding to generate the evaluation report from the Evidence Pack.
Diclofenac Sodium: Repurposing Evaluation on Hold — No TxGNN Predictions Available
One-Sentence Summary
Diclofenac Sodium is a well-established non-steroidal anti-inflammatory drug (NSAID), widely used for pain and inflammatory conditions worldwide. However, the TxGNN pipeline returned no predicted new indications for this compound in the current evidence pack. Without a repurposing target, clinical trial evidence, or literature linkage, a full evaluation cannot be completed at this stage.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not populated in evidence pack (DrugBank query returned 1 result but data was not mapped) |
| Predicted New Indication | Not available — predicted_indications array is empty |
| TxGNN Prediction Score | Not available |
| Evidence Level | L5 — Model prediction not generated; no supporting studies |
| New Zealand Market Status | Not marketed (0 authorisations on record) |
| Number of Authorisations | 0 |
| Recommended Decision | Hold |
New Zealand Market Information
No marketing authorisations were found for Diclofenac Sodium in the New Zealand regulatory database at the time of query (2026-03-29).
Note: Diclofenac Sodium is a globally common NSAID with regulatory approval in many jurisdictions. A result of 0 licences is unexpected and likely reflects a data mapping issue in the pipeline rather than genuine absence from the market. Manual verification against Medsafe's online register is recommended before drawing conclusions.
Safety Considerations
Safety data (key warnings, contraindications, and drug interactions) was not successfully mapped from the package insert or DDI database into this evidence pack.
Please refer to the approved package insert and Medsafe product monograph for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The evidence pack contains no TxGNN-predicted indications, no populated original indication text, no safety data, and no New Zealand licensing records — making it impossible to conduct a meaningful repurposing evaluation at this time.
To proceed, the following is needed:
- Resolve pipeline mapping failure: DrugBank and TFDA package insert queries both returned 1 result (
result_status: success) but no data was written intodrug.original_moa,drug.drugbank_id, ortaiwan_regulatory.licenses— investigate the ETL step between raw query results and Evidence Pack serialisation - Re-run TxGNN prediction: Confirm that Diclofenac Sodium is present in the knowledge graph node list; if the drug ID lookup failed silently, that would explain why
predicted_indicationsis empty - Retrieve MOA from DrugBank: The DrugBank query succeeded — extract mechanism of action (COX-1/COX-2 inhibition), categories, and approved indications from the cached result
- Verify New Zealand market status manually: Check the Medsafe Databank directly; 0 licences for a common NSAID is anomalous
- Re-run DDI query: DDI returned
not_found— consider querying under alternate drug names (e.g. "diclofenac", "voltaren") and verifying the drug name normalisation stepDisclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.